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Introduction {#sec1-1}
============

Acute cerebral infarction (ACI) is one of the most common clinical cardiovascular, cerebrovascular, and neurological diseases, and accounts for about 70% of all stroke (Cheng et al., 2015). It is estimated that ACI may lead to 6.2 million mortalities annually worldwide, and it is fast becoming a major challenge to public health (Inoue et al., 2006; You et al., 2017). An ACI can increase blood viscosity and cause thrombus formation and vascular occlusion in the brain, followed by ischemia and hypoxia in brain tissues, resulting in brain dysfunction (Li et al., 2018; Schregel et al., 2018). Patients with ACI have many health problems that may be associated with age, sex, dementia, stroke severity degree, and other factors (Nakamura et al., 2018).

Currently, conventional therapy with western medicines primarily consist of thrombolysis, controlling the cerebral edema, preventing and treating complications, restoring blood supply to the ischemic area, controlling hypertension, improving microcirculation, reducing blood viscosity, and the use of cerebral protection agents (Cheng et al., 2015). Among these therapies, thrombolytic therapy and cerebral protection are two effective choices for the treatment of ACI. Thrombolytic therapy is generally used as the initial therapy (Tang et al., 2015), and was the Grade-I recommendation in the guide for the diagnosis and treatment of ACI in China in 2010 based on the national conditions and clinical experience (Liu et al., 2018). However, because thrombolysis has a relatively short therapeutic time window, many patients miss this effective time window for thrombolytic treatment. Furthermore, researchers are increasingly demonstrating that revascularization alone does not assure positive clinical outcomes; meanwhile, numerous studies have indicated that neuroprotectants can give beneficial results, at least in animal experiments (Rong et al., 2013; Li et al., 2016).

Cattle encephalon glycoside and ignotin (CEGI) injection (drug approval No. H22025046; Jilin Sihuan Pharmaceutical Co. Ltd., Jilin, China) was approved by the Chinese Food and Drug Administration in 2003. It is a compound preparation formed by a combination of muscle extract from healthy rabbits and brain gangliosides from cattle, and it is used as a neuroprotectant in the treatment of central and peripheral nerve injuries in China. CEGI is mainly composed of polypeptides, a number of gangliosides, free amino acids, and nucleic acids. Monosialotetrahexosy-1 ganglioside (GM-1), an active component in CEGI, is effective in the treatment of nervous system diseases, including in the treatment of ACI (Tang et al., 2006). Furthermore, polypeptides were reported to have a therapeutic effect in mouse models of ischemic brain damage, and these are also a component of CEGI (Baek et al., 2014). However, as yet there have been no high-level clinical studies in large samples that investigate the use of CEGI in ACI (Li et al., 2016). Therefore, the present study was conducted to evaluate the effectiveness and safety of CEGI in the treatment of ACI.

Participants and Methods {#sec1-2}
========================

Study design {#sec2-1}
------------

This was a prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. The study was conducted in accordance with the *Declaration of Helsinki*, and was approved by the Ethical Committee of Peking University Third Hospital, China (approval No. 2013-068-2) on May 20, 2013 (**Additional file 1**). Written informed consent (**Additional file 2**) was obtained from the patients or their family members. The study was registered at the Chinese Clinical Trial Registry (registration No. ChiCTR1800017937), and followed the CONsolidated Standards Of Reporting Trials (CONSORT) guidelines (**[Additional file 3](#T6){ref-type="table"}**).

###### 

CONSORT checklist of information to include when reporting a randomised trial

  Section/Topic                             Item No   Checklist item                                                                                                                                                                                Reported on page No
  ----------------------------------------- --------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Title and abstract**                                                                                                                                                                                                                            
                                            1a        Identification as a randomised trial in the title                                                                                                                                             1-2
                                            1b        Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)                                                                       1-2
  **Introduction**                                                                                                                                                                                                                                  
  Background and                            2a        Scientific background and explanation of rationale                                                                                                                                            2
  objectives                                2b        Specific objectives or hypotheses                                                                                                                                                             3
  **Methods**                                                                                                                                                                                                                                       
  Trial design                              3a        Description of trial design (such as parallel, factorial) including allocation ratio                                                                                                          3
                                            3b        Important changes to methods after trial commencement (such as eligibility criteria), with reasons                                                                                            3
  Participants                              4a        Eligibility criteria for participants                                                                                                                                                         3
                                            4b        Settings and locations where the data were collected                                                                                                                                          3
  Interventions                             5         The interventions for each group with sufficient details to allow replication, including how and when they were actually administered                                                         6
  Outcomes                                  6a        Completely defined pre-specified primary and secondary outcome measures, including how and when they                                                                                          6
                                                      were assessed                                                                                                                                                                                 
                                            6b        Any changes to trial outcomes after the trial commenced, with reasons                                                                                                                         3
  Sample size                               7a        How sample size was determined                                                                                                                                                                3
                                            7b        When applicable, explanation of any interim analyses and stopping guidelines                                                                                                                  3
  Randomisation:                                                                                                                                                                                                                                    
   Sequence                                 8a        Method used to generate the random allocation sequence                                                                                                                                        3
    generation                              8b        Type of randomisation; details of any restriction (such as blocking and block size)                                                                                                           4
   Allocation                               9         Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned   4
    concealment                                                                                                                                                                                                                                     
    mechanism                                                                                                                                                                                                                                       
   Implementation                           10        Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions                                                                       4
  Blinding                                  11a       If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how                                                      4
                                            11b       If relevant, description of the similarity of interventions                                                                                                                                   7
  Statistical methods                       12a       Statistical methods used to compare groups for primary and secondary outcomes                                                                                                                 7
                                            12b       Methods for additional analyses, such as subgroup analyses and adjusted analyses                                                                                                              7
  **Results**                                                                                                                                                                                                                                       
  Participant flow (a diagram is strongly   13a       For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome                                                5
  recommended)                              13b       For each group, losses and exclusions after randomisation, together with reasons                                                                                                              7
  Recruitment                               14a       Dates defining the periods of recruitment and follow-up                                                                                                                                       7
                                            14b       Why the trial ended or was stopped                                                                                                                                                            7
  Baseline data                             15        A table showing baseline demographic and clinical characteristics for each group                                                                                                              8
  Numbers analysed                          16        For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups                                                       9
  Outcomes and estimation                   17a       For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)                                             10
                                            17b       For binary outcomes, presentation of both absolute and relative effect sizes is recommended                                                                                                   11
  Ancillary analyses                        18        Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing                                                                                    12
                                                      pre-specified from exploratory                                                                                                                                                                
  Harms                                     19        All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)                                                                                         13
  **Discussion**                                                                                                                                                                                                                                    
  Limitations                               20        Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses                                                                              16
  Generalisability                          21        Generalisability (external validity, applicability) of the trial findings                                                                                                                     14
  Interpretation                            22        Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence                                                                                 15
  **Other information**                                                                                                                                                                                                                             
  Registration                              23        Registration number and name of trial registry                                                                                                                                                16
  Protocol                                  24        Where the full trial protocol can be accessed, if available                                                                                                                                   16
  Funding                                   25        Sources of funding and other support (such as supply of drugs), role of funders                                                                                                               16

Sample size calculation {#sec2-2}
-----------------------

Based on previous literature (Wang et al., 2006), the ratio of good clinical outcome rates (modified Rankin Scale (mRS) scores) between the placebo and CEGI groups (26.76 *vs.* 50.64%, respectively) was used to determine the ratio of case numbers for the CEGI and placebo groups (3:1). On this basis, the power was set at 80% and α = 0.05. Power Analysis and Sample Size (PASS, 2008, NCSS, LLC., Kaysville, UT, USA) software was used to calculate the sample size of the CEGI group as 198 cases and the placebo group as 66 cases. Based on a shedding rate of approximately 20% and group randomization, it was calculated that approximately 320 cases were needed for this study.

Participants {#sec2-3}
------------

A total of 319 eligible patients were prospectively recruited from 16 centers (Peking University Third Hospital; The First Affiliated Hospital of Nanchang University; Beijing Chao-Yang Hospital, Capital Medical University; The Second Hospital of Jilin University; Baotou Central Hospital; Jining No.1 People's Hospital; Affiliated Hospital of Jining Medical University; The First Hospital of Luoyang City; Zhuozhou Hospital; Xuzhou Central Hospital; General Hospital of Xuzhou Mining Group; Huang Gang Central Hospital; The First Hospital of Shijiazhuang City; People's Hospital of Yichun City; Affiliated Hospital of Jinggangshan University; Jiangxi Hospital of Integrated Chinese and Western Medicine) in China from October 2013 to May 2016. Patients were randomized using a computer-generated randomization sequence (3:1) to either the CEGI group (*n* = 239) or the placebo group (*n* = 80). A flowchart for the study population is shown in **[Figure 1](#F1){ref-type="fig"}**. Treatment assignment was masked from all investigators, study personnel, and patients throughout the trial. Patients eligible for this study (a) were aged between 18 and 75 years old who diagnosed with atherosclerotic cerebral infarction; (b) were within 48 hours after ACI onset; (c) if they had a history of limb paralysis caused by cerebrovascular disease, their mRS score was 0--1 (Uyttenboogaart et al., 2005); (d) had a score of 5--22 points on the National Institutes of Health Stroke Scale (NIHSS) (Fischer et al., 2005); and (e) signed an informed consent form. Patients were excluded if they: (a) were diagnosed with a transient ischemic attack, non-responsible multi lacunar infarction, cerebral hemorrhage after infarction, subarachnoid hemorrhage, and/or post-circulation ischemia; (b) had hemiplegia caused by a brain tumor, brain injury, brain parasitic disease, or metabolic disorder, or a cerebral embolism caused by rheumatic heart disease, coronary heart disease, or other heart disease with atrial fibrillation; (c) had gangliosidoses (such as Tay-Sachs diesease); (d) were thrombolytic patients or peptic ulcer patients who could not take aspirin; (e) had severe primary cardiovascular, liver (alanine aminotransferase or aspartate transaminase exceeding a 1.5-fold upper range value), renal (blood urea nitrogen (BUN) exceeding a 1.2-fold upper range value, creatinine exceeding a 2-fold upper range value), hematopoietic, and/or endocrine system diseases; (f) presented allergies to the study drug or protein; (g) were drug- or alcohol-dependent; (h) were pregnant or lactating; or (i) had participated in other clinical trials within the previous 3 months.

![Study design and CONSORT diagram showing the flow of participants.\
CEGI: Cattle encephalon glycoside and ignotin; CONSORT: CONsolidated Standards Of Reporting Trials.](NRR-15-1266-g002){#F1}

Interventions {#sec2-4}
-------------

All patients were given standard care once daily for 14 days, including 200 mg aspirin enteric-coated tablet (drug approval No. J20080078, Bayer Medical and Health Co., Ltd., Beijing, China) and 20 mg atorvastatin calcium (drug approval No. YBH19122005, Pfizer Pharmaceuticals Ltd., Beijing, China), both orally, and intravenous infusion of 250--500 mL 0.9% sodium chloride containing 40 mg sodium tanshinone IIA sulfonate (drug approval No. WS-10001-(HD-1014)-2002, Shanghai First Biochemical Pharmaceutical Co., Ltd., Shanghai, China). Based on conventional treatment, the CEGI and placebo groups were given 12 mL CEGI (1 mL contained 2.56--3.84 mg polypeptides, 40--60 µg gangliosides (measured by lipid-bound sialic acid), 1.40--1.90 mg free amino acids, 0.75--1.10 mg total nitrogen, and 0.24--0.36 mg nucleic acids) or 12 mL sterile water, respectively, in an intravenous drip of 250 mL 0.9% sodium chloride (2 mL/min) once daily for 14 days, with an interval between other intravenous drug drips of 2 hours. During the study, dehydrating agents, diuretics, antihypertensive drugs, lipid-lowering drugs, antidiabetics, vitamin B, and antibiotics were allowed, while heparins, anti-fibrinogen drugs, and neuroprotectants (such as cytophosphate, edaravone, duxil, and piracetam) were prohibited.

Outcome measures {#sec2-5}
----------------

Basic information and disease history of all patients was recorded before treatment. The primary outcome measure was the mRS score at 3 months after treatment. Based on the mRS score, 0--1 was defined as "no symptoms or no significant disability" (0--1, good outcome), 2--3 was defined as "slight/moderate disability", and 4--6 was defined as "severe disability or dead" (\> 1, poor outcome).

The secondary endpoints were the scores from activities of daily living in the Barthel Index (BI) (Quinn et al., 2011) and the NIHSS scores. These were evaluated before treatment and on days 7, 14, and 90 after treatment. BI scores were out of 100, and were classified as follows: (1) 100, independence; (2) 75--95, mild dependence; (3) 50--70, moderate dependence; (4) 25--45, severe dependence; and (5) 0--20, exclusive dependence. The NIHSS score evaluated the degree of neurological deficiency. Based on the NIHSS clinical efficacy standard, the degrees of recovery were classified as follows: (1) 91--100% decrease of NIHSS, recovery; (2) 46--90% decrease, significant progress; (3) 18--45% decrease, progress, (4) ≤ 17% increase or decrease, no change; and (5) \> 18% increase, deterioration. In addition, patients were divided into three groups based on their baseline NIHSS scores: mild (NIHSS score \< 7), moderate (NIHSS score 8--16), and severe (NIHSS score 17--22) stroke. In this study, there were no patients with severe stroke in the placebo group, so the subgroup analysis for severe stroke could not be performed; thus, only the mild and moderate subgroups were statistically analyzed to evaluate the efficacy of CEGI in different degrees of ACI.

The safety indicators used were the detection of alterations in vital signs, routine blood and urine examinations, liver and kidney function parameters, and electrocardiographic examinations before and during the treatment. Adverse effects were recorded and timely treatment was administered if needed. Patients with adverse effects were followed up until the adverse effects were resolved.

Statistical analysis {#sec2-6}
--------------------

Three statistical analysis sets were constructed. The efficacy analysis set was defined as the full analysis set (FAS), which included all patients from the CEGI group (who received at least one dose of the study drug and had at least one follow-up record) and all patients from the placebo group. As a subset of FAS, the per-protocol set (PPS) included all patients who had good compliance, did not take prohibited drugs, and completed the case report form. The safety analysis set (SS) included those patients who received at least one dose of the study drug and had baseline safety data and at least one follow-up safety record. The primary and secondary efficacy indicators were analyzed in the FAS and PPS, while the SS was the main set used for safety assessment in this study.

Statistical analysis was performed using SAS 9.1.3 software (SAS Institute, Inc., Cary, NC, USA). Continuous variables were presented as the number of cases and the mean, standard deviation, median, minimum, and maximum values. For categorical variables, data were expressed as the number of categorical cases or percentages, and analyzed using a Z test. The one-sided Cochran--Mantel--Haenszel chi-squared test was used for the statistical comparison of mRS scores between the two groups. A rank-sum test and independent *t*-test were performed at baseline and on days 7, 14, and 90 to detect differences in the activities of daily living and NIHSS scores between the two groups. The paired *t*-test was used to investigate differences in blood pressure before and after treatment in both groups, and the Fisher's exact test was used to test differences in adverse events between the two groups. A level of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Compliance analysis and baseline characteristics of ACI patients with CEGI and placebo treatment {#sec2-7}
------------------------------------------------------------------------------------------------

Trial medication was given to 319 patients, with 239 receiving CEGI and 80 receiving placebo. **[Figure 1](#F1){ref-type="fig"}** shows the patient flow and identifies reasons for dropout from the study. The rate of discontinuation was 3.95% (14/319). The final follow-up rates in the CEGI group and in the placebo group were 95.4% (228/239) and 96.25% (77/80), respectively, with no significant difference between the two groups (*P* \> 0.05). All baseline characteristics were well balanced across the two groups and there were no significant differences in these characteristics (**[Table 1](#T1){ref-type="table"}**). Furthermore, there were 307 patients in the FAS analysis (CEGI group, *n* = 229; placebo group, *n* = 78), 291 patients in the PPS analysis (CEGI group, *n* = 218; placebo group, *n* = 73), and 315 patients in the SS analysis (CEGI group, *n* = 236; placebo group, *n* = 79).

###### 

Comparison of baseline data of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group

  Baseline data                                      CEGI group (*n* = 239)   Placebo group (*n* = 80)   Statistics     *P*-value
  -------------------------------------------------- ------------------------ -------------------------- -------------- -----------
  Age (yr)                                           61.2±9.2                 63.2±8.28                  *t*=1.74       0.083
  Height (cm)                                        166.3±6.94               165.1±7.11                 *Z*=1.08       0.282
  Weight (kg)                                        66.3±9.52                66.3±8.39                  *Z*=0.222      0.824
  Sex                                                                                                    *χ*^2^=1.39    0.234
   Male                                              155 (64.9)               46 (57.5)                                 
   Female                                            84 (35.1)                34 (42.5)                                 
  Respiratory rate (times/min)                       18.9±1.49                18.8±1.57                  *Z*=0.179      0.858
  Body temperature (°C)                              36.5±0.33                36.5±0.32                  *Z*=0.304      0.761
  Systolic blood pressure (mmHg)                     146.5±20.8               147.4±23.1                 *Z*=0.237      0.812
  Diastolic blood pressure (mmHg)                    86.7±13                  84.7±12.2                  *Z*=1.26       0.207
  Time of progression (h)                            22.5±13.8                25.1±14.5                  *Z*=1.49       0.136
  Allergic history                                                                                       *χ*^2^=0.316   0.854
   Yes                                               7 (2.93)                 3 (3.75)                                  
   No                                                220 (92.1)               72 (90.0)                                 
   Unknown                                           12 (5.02)                5 (6.25)                                  
  Previous medical history                                                                               *χ*^2^=0.009   0.926
   Yes                                               139 (58.2)               47 (58.8)                                 
   No                                                100 (41.8)               33 (41.2)                                 
  Barthel Index scores                               64.1±18.8                63.38±20.2                 *Z*=0.117      0.907
  National Institute of Health Stroke Scale scores   8.10±2.68                7.69±2.10                  *Z*=1.07       0.286
  Modified Rankin Scale scores                       2.76±0.78                2.80±0.85                  *Z*=0.219      0.827

Data are expressed as the mean ± SD except sex, allergic history, and previous medical history \[*n* (%)\]. The one-sided Cochran--Mantel-- Haenszel (CMH) chi-squared test and independent *t*-test were used.

Efficacy of CEGI treatment in patients with ACI {#sec2-8}
-----------------------------------------------

### mRS scores {#sec3-1}

There was a significant difference between the CEGI and placebo groups in the primary endpoint mRS scores on day 90 after treatment (*P* \< 0.05), in favor of the CEGI group. The rate of patients with good outcomes was higher in the CEGI group than in the placebo group on day 90 after treatment (FAS, *P* = 0.016; PPS, *P* = 0.011; **[Figure 2A](#F2){ref-type="fig"}**). The rate of disability in the CEGI group was lower than in the placebo group on day 90 after treatment (FAS, *P* = 0.007; PPS, *P* = 0.005; **[Figure 2B](#F2){ref-type="fig"}**). For the subgroup of patients with mild stroke, there was no significant difference in the rate of disability between the CEGI and placebo groups on day 90 after treatment (FAS, *P* = 0.267; PPS, *P* = 0.232; **[Figure 3A](#F3){ref-type="fig"}**). In contrast, in the subgroup of patients with moderate stroke, there was significant difference in the rate of disability between the two groups (FAS, *P* = 0.001; PPS, *P* = 0.001; **[Figure 3B](#F3){ref-type="fig"}**).

![Comparison of modified Rankin Scale scores between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group on days 90; (A) the rate of good outcomes/poor outcomes and (B) the degree of disability in acute cerebral infarction patients.\
The efficacy analysis set was defined as the full analysis set (FAS) (CEGI group, *n* = 229; placebo group, *n* = 78) and the per-protocol set (PPS) (CEGI group, *n* = 218; placebo group, *n* = 73). The Cochran--Mantel--Haenszel chi-squared test was used to compare the rates of outcomes in the CEGI and placebo groups; the rank-sum test was used to compare the rates of disability in the CEGI and placebo groups. \**P* \< 0.05, \*\**P* \< 0.01.](NRR-15-1266-g003){#F2}

![Comparison of the degree of disability using modified Rankin Scale scores of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) subgroup and the placebo subgroup on day 90.\
(A, B) Degree of disability in the mild (A) and moderate (B) stroke subgroups in the full analysis set (FAS) (CEGI group, *n* = 229; placebo group, *n* = 78) and the per-protocol set (PPS) (CEGI group, *n* = 218; placebo group, *n* = 73). The rank-sum test was used to compare the rates of disability between the CEGI and placebo subgroups. \**P* \< 0.05.](NRR-15-1266-g004){#F3}

### NIHSS scores {#sec3-2}

In the FAS analysis, the NIHSS scores of both groups at baseline and on days 7 and 14 after treatment were not significantly different (*P* \> 0.05), while there was significant difference in the NIHSS scores on day 90 after treatment between the two groups (*P* = 0.003; **[Table 2](#T2){ref-type="table"}**). In the PPS analysis, the NIHSS scores of both groups at baseline and on day 7 were not significantly different, while there were significant differences in the NIHSS scores on days 14 and 90 between the two groups (day 14, *P* = 0.046; day 90, *P* = 0.003), meaning that the improvement of neurological disorder became more apparent over time. Furthermore, **[Table 3](#T3){ref-type="table"}** shows the NIHSS scores in the CEGI and placebo subgroups on days 7, 14, and 90 in both the FAS and PPS analyses. For the FAS analysis, when the degree of recovery using NIHSS scores were compared, there were significant differences between the groups on days 14 and 90, the degree of recovery in the CEGI group was higher than in the placebo group (day 14, *P* \< 0.001; day 90, *P* = 0.003; **[Figure 4](#F4){ref-type="fig"}**). Similar results were observed in the PPS analysis (day 14, *P* = 0.005; day 90, *P* = 0.003; **[Figure 5](#F5){ref-type="fig"}**).

###### 

Comparison of National Institutes of Health Stroke Scale scores of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) and placebo groups at baseline and on days 7, 14, and 90 after treatment

                                    CEGI group   Placebo group   *t*-value   *P*-value
  -------------- ------------------ ------------ --------------- ----------- -------------
  FAS analysis   Before treatment   8.08±2.66    7.68±2.12       1.35        0.177
                 After treatment                                             
                  Days 7            5.96±2.4     6.42±4.99       --0.79      0.433
                  Days 14           3.69±2.2     4.88±5.19       1.95        0.054
                  Days 90           2.54±1.9     3.53±2.65       --2.99      0.004^\*\*^
  PPS analysis   Before treatment   8.14±2.67    7.74±2.16       1.28        0.203
                 After treatment                                             
                  Days 7            5.99±2.41    5.96±2.35       0.08        0.933
                  Days 14           3.71±2.2     4.32±2.37       --2         0.046^\*^
                  Days 90           2.51±1.85    3.53±2.66       --3.04      0.003^\*\*^

Data are expressed as the mean ± SD, and analyzed using the rank-sum test and *t*-test. \**P* \< 0.05, \*\**P* \< 0.01. The full analysis set (FAS) consisted of 229 and 78 cases in in the CEGI and placebo groups, respectively. The per-protocol set (PPS) consisted of 218 and 73 cases in the CEGI and placebo groups, respectively.

###### 

Comparison of National Institutes of Health Stroke Scale scores of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group on days 7, 14, and 90 after treatment

                           Mild stroke subgroup   *t*-value   *P*-value   Moderate stroke subgroup   *t*-value   *P*-value            
  -------------- --------- ---------------------- ----------- ----------- -------------------------- ----------- ----------- -------- -----------------
  FAS analysis   Days 7    4.85±1.59              4.71±1.73   --0.52      0.605                      7.22±2.55   9.17±6.98   --1.5    0.145
                 Days 14   3.04±1.68              3.36±1.69   --1.1       0.272                      4.42±2.48   7.27±7.52   --2.05   0.049^\*^
                 Days 90   2.08±1.72              2.49±1.83   --1.36      0.174                      3.05±1.96   5.21±2.93   --3.75   \< 0.001^\*\*^
  PPS analysis   Days 7    4.88±1.61              4.73±1.75   0.5         0.621                      7.2±2.56    7.93±1.78   --1.73   0.089
                 Days 14   3.05±1.67              3.31±1.68   --0.88      0.38                       4.42±2.48   5.93±2.46   --2.85   0.005^\*\*^
                 Days 90   2.09±1.7               2.49±1.79   --1.32      0.188                      2.98±1.9    5.21±2.99   --3.76   \< 0.0001^\*\*^

Data are expressed as the mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 (rank-sum test and independent *t*-test). The full analysis set (FAS) in the mild stroke subgroup consisted of 122 and 48 cases in the CEGI and placebo groups, respectively; in the moderate stroke subgroup it consisted of 107 cases in the CEGI group and 30 cases in the placebo group. The per-protocol set (PPS) in the mild stroke subgroup consisted of 114 cases in the CEGI group and 45 in the placebo group; in the moderate stroke subgroup it consisted of 104 cases in the CEGI group and 28 cases in the placebo group.

![Full analysis set (FAS) analysis of the degree of recovery using the National Institutes of Health Stroke Scale scores of acute cerebral infarction patients in the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group on days 14 (A) and 90 (B) after treatment.\
The rank-sum test was used for comparison. The FAS consisted of 229 and 78 cases in the CEGI and placebo groups, respectively.](NRR-15-1266-g005){#F4}

![Per-protocol set (PPS) analysis of the degree of recovery using National Institutes of Health Stroke Scale scores of acute cerebral infarction patients in the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group on days 14 (A) and 90 (B) after treatment.\
The rank-sum test was used for comparison. The PPS consisted of 218 and 73 cases in the CEGI and placebo groups, respectively.](NRR-15-1266-g006){#F5}

### BI scores {#sec3-3}

In both the FAS and PPS analyses, there were significant differences in BI scores on days 14 and 90 after treatment between the CEGI and placebo groups (*P* \< 0.05; **[Table 4](#T4){ref-type="table"}**).

###### 

Comparison of Barthel Index scores of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group at baseline and on days 7, 14, and 90 after treatment

                                    CEGI group   Placebo group   *t*-value   *P*-value
  -------------- ------------------ ------------ --------------- ----------- -----------
  FAS analysis   Before treatment   64.2±18.2    63.5±19.7       0.28        0.778
                 After treatment                                             
                  Days 7            72.9±16.2    69.5±19.9       1.37        0.174
                  Days 14           82.2±14.6    76.6±18.2       2.45        0.016^\*^
                  Days 90           89.8±10.5    84.8±16.2       2.52        0.013^\*^
  PPS analysis   Before treatment   64.0±18.3    64.3±18.4       --0.14      0.889
                 After treatment                                             
                  Days 7            72.7±15.9    70.8±17.5       0.87        0.383
                  Days 14           82.1±14.7    77.8±16.1       2.1         0.037^\*^
                  Days 90           89.9±10.5    84.9±16.1       2.45        0.016^\*^

Data are expressed as the mean ± SD. \**P* \< 0.05 (rank-sum test and independent *t*-test). The full analysis set (FAS) consisted of 229 and 78 cases in the CEGI and placebo groups, respectively; the per-protocol set (PPS) consisted of 218 and 73 cases in the CEGI and placebo groups, respectively.

Safety of CEGI treatment in patients with ACI {#sec2-9}
---------------------------------------------

### Analyses of vital signs and laboratory examinations {#sec3-4}

There were no significant differences between the CEGI and placebo groups in body temperature, respiration rate, systolic blood pressure, and diastolic blood pressure before and after treatment. However, after treatment, blood pressure (both systolic and diastolic) in CEGI and placebo groups was significantly lower than it was before treatment (*P* \< 0.05; **[Table 5](#T5){ref-type="table"}**). This lowering of blood pressure may be because: (1) blood pressure was often elevated with cerebral infarction, for various reasons. To protect cerebral tissue in the ischemic area, blood pressure was not treated at the acute stage, so baseline blood pressure was higher. (2) In a more stable condition, stress factors were eliminated and antihypertensive drugs were used, so blood pressure dropped significantly after treatment.

###### 

Blood pressure before and after treatment, and the incidence of adverse events in acute cerebral infarction patients between the glycoside and ignotin (CEGI) and placebo groups

                                                           CEGI group (*n* = 236)   Placebo group (*n* = 79)   Statistics   *P*-value
  -------------------------------------------------------- ------------------------ -------------------------- ------------ -----------
  Systolic blood pressure (mmHg)                                                                                            
   Before treatment                                        146±20.8                 147.3±23.2                 *t*=--0.29   0.768
   On days 90 after treatment                              138.2±14.7               137.7±13.8                 *t*=0.27     0.787
   Change                                                  --8.39±15.4              --8.74±15.3                *t*=0.17     0.862
   *P*-value                                               \< 0.05                                                          
  Diastolic blood pressure (mmHg)                                                                                           
   Before treatment                                        86.6±13                  84.9±12.1                  *t*=1.02     0.31
   On days 90 after treatment                              81.8±9.3                 81.1±9.0                   *t*=0.63     0.528
   Change                                                  --4.86±11.7              --3.49±10.2                *t*=--0.93   0.354
   *P*-value                                               \< 0.05                                                          
  Adverse event \[*n* (%)\]                                                                                                 
   All adverse events                                      98 (41.5)                29 (36.7)                  *F*=0.51     \> 0.05
   Serious adverse event                                   2 (0.85)                 1 (1.27)                                
   Drug-related adverse events                             0                        0                          *F*=1.0000   
   Drug-unrelated adverse events                           98 (41.5)                29 (36.7)                               
   Adverse events leading to the suspension of the study   0                        0                                       

Data are expressed as the mean ± SD, except adverse events. The paired *t*-test was used to test differences in blood pressure between before and after treatment in both groups, and Fisher's exact test was used to test differences in adverse events between the CEGI and placebo groups.

There were no significant differences between the two groups in results from routine blood and urine examinations, liver and kidney function parameters, and electrocardiographic examinations (*P* \> 0.05). In the CEGI group, platelet elevation was detected in one patient (0.42%) and urinary erythrocyte elevation was detected in three patients (1.27%). In the placebo group, aspartate aminotransferase elevation was detected in two patients (2.53%), alanine aminotransferase elevation was detected in two patients (2.53%), alkaline phosphatase elevation was detected in one patient (1.27%), and glutamyl transpeptidase elevation was detected in one patient (1.27%).

### Adverse effects {#sec3-5}

Adverse effects were observed in 98 patients (41.5%) in the CEGI group and 29 patients (36.7%) in the placebo group. Among them, serious adverse effects occurred in two patients from the CEGI group (0.85%) and one patient from the placebo group (1.27%). There were no drug-related adverse effects (adverse reactions). Adverse effects did not result in study termination for any patients in the two groups. There was no significant difference between the two groups in adverse effects (**[Table 5](#T5){ref-type="table"}**).

Discussion {#sec1-4}
==========

ACI is a complex disease with high rates of mortality and disability, and represents a significant threat to human life. Its pathophysiological mechanisms are associated with lactate accumulation, free radical release, intracellular calcium overload, inflammatory process, apoptosis and other effects (Del Bene et al., 2012; Zhao et al., 2019). Previously, rapid thrombolysis and early cerebral protection are considered the two most important methods in the treatment of cerebral infarction (Broussalis et al., 2012; Okabe and Miyamoto, 2018). However, thrombolytic therapy for acute stroke is a complex issue, balancing the benefit of the reversal of ischemia against the risk of symptomatic cerebral hemorrhage, which is a major life-threatening complication of thrombolytics (Vidale and Agostoni, 2014). Recently, much research has therefore focused on the use of neuroprotectants in ACI treatment. Furthermore, considering the complex pathophysiological mechanisms of this disease, a multi-target drug therapy may lead to better efficacy in the treatment of ACI.

CEGI is a multi-target neuroprotective agent that includes GM-1, carnosine, free amino acids, and hypoxanthine. By acting on various targets in ACI, CEGI may interrupt the development of the pathophysiological processes that lead to poor outcomes following ACI. Most CEGI components can directly pass through the blood-brain barrier, ensuring a pharmaceutical effect in the treatment of central nervous system diseases. As a member of the ganglioside family, GM-1 is involved in optimal myelin formation and central axon stability (Stevenson et al., 2009), and one study reported that exogenous GM-1 treatment improved myelin sheath damage (Rong et al., 2013). A previous safety evaluation also showed that low-dose and combined use of GM-1 was possibly a better choice than routine medication in clinical practice for treatment of patients with acute ischemic cerebral stroke (Candelise and Ciccone, 2002; Zhao et al., 2016). Carnosine, another important component of CEGI, might reduce brain damage after ischemic stroke by maintaining normal glutathione levels and decreasing levels and activity of matrix metalloproteinase (Rajanikant et al., 2007). Carnosine may also suppress myelin degeneration, as was indicated in a pre-clinical study (Ma et al., 2012). Other components of CEGI, such as free amino acids and hypoxanthine, might contribute to the development and maintenance of the nervous system. Thus, because of its multiple active components, CEGI may perform its neuroprotective effect by interfering with a number of different targets, causing it to be more potent and effective than each component alone would be.

Recently, many researchers have studied the efficacy of neuroprotective reagents in extending the therapeutic time window for thrombolysis, which may inhibit cell death and block reperfusion injury (Xu et al., 2018). CEGI has been widely used in the treatment of central and peripheral nerve injuries with a wide safety margin and few side effects, including in the treatment of Alzheimer's disease (Gao et al., 2015). Moreover, possible therapeutic mechanisms of CEGI have been reported in pre-clinical studies, suggesting that CEGI might perform multiple forms of cerebral protection by intervening in multiple targets during the occurrence and development of nervous system injury (Li et al., 2016). Therefore, the present study aimed to obtain more clinical evidence for CEGI in the treatment of ACI, as well as to further evaluate the effectiveness and safety of CEGI in ACI treatment. In the current study, 319 patients from 16 centers in China were enrolled. The patient population was homogeneous, as demonstrated by their similar baseline characteristics, minimal premorbid neurological deficits, and similar disease processes.

The results of this study demonstrated the neuroprotective effect of CEGI in ACI. On day 90 after treatment, there were significant differences in term of the decreased of mRS scores between CEGI group and placebo group. The comparison of NIHSS scores between the CEGI and placebo groups indicated a gradual decrease in scores in both groups starting from day 7. Furthermore, the degree of recovery was more pronounced in the CEGI group compared with the placebo group on days 14 and 90 after treatment. These findings indicated that a 2-week treatment of CEGI combined with basic pharmaceutical therapy may contribute to the recovery from neurological impairment and decrease disability rates in patients with ACI, and that this curative effect might be preserved for a long time. In addition, BI scores gradually increased from day 7 after treatment in both groups, and the scores in the CEGI group reached higher levels compared with the placebo group; on day 14 after treatment, there was a significant difference between the groups, suggesting that subjects in the CEGI group achieved greater improvement in functional outcomes than those in the placebo group. CEGI treatment of ACI was beneficial in improving the self-maintenance ability and quality of life of patients. In addition, NIHSS and mRS scores of the subgroups indicated that CEGI led to better outcomes in the treatment of moderate stroke patients compared with mild stroke patients.

In the present study, the enrolled subjects had an ACI less than 48 hours before receiving treatment; therefore, the early administration of CEGI might be a critical factor for the treatment to be successful. In addition, a 14-day course of treatment might help to guarantee its efficacy, which may be maintained for a long time after CEGI administration. All the safety analyses in the present study supported CEGI as a safe treatment for patients with ACI. However, our study had limitations: first, the small sample size; and second, the short duration of follow-up. Therefore, in a future study, we will use a larger sample size and increase the duration of follow-up to confirm the results of the current study.

In conclusion, the present study showed that CEGI treatment of ACI was safe, decreased disability rates and neurological impairments in patients, and improved patients' daily living activities. CEGI may therefore be a safe and effective treatment for ACI patients, especially in moderate stroke patients.
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